On Track to Report Topline Data in Mid-2019 for Potential New Baseline Levodopa Treatment JERUSALEM , Oct. 22, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces the completion of patient enrollment in the Company's pivotal Phase 3 clinical trial

JERUSALEM , Sept. 25, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that three posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming

JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences.  Oppenheimer 2018 Fall Summit - Focused on Specialty Pharma and Rare Disease Date:

Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the

Former LabCorp CFO Brings Wealth of Financial Experience JERUSALEM, June 29, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors.  Mr.

JERUSALEM , May 31, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NETC) (TASE: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City . Jeffrey A.

More than 350 patients enrolled in pivotal Phase 3 ACCORDANCE trial and more than 80% of eligible patients entered the open label extension study JERUSALEM , May 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) (" Intec " or "the Company") today announces financial results for

JERUSALEM, April 24, 2018 /PRNewswire/ -- Intec Pharma LTD (NASDAQ, TASE:NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at

Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares JERUSALEM, April 13, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price

JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. The gross proceeds of the offering are expected to be